Recursion Pharmaceuticals (RXRX) is back in focus after reporting fourth quarter and full year 2025 results, highlighting much higher quarterly revenue, a smaller net loss, and fresh commentary on its ...

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI ...

American Airlines quietly ended the ability for customers traveling on basic economy tickets to earn miles and status. Basic economy tickets are airlines' most restrictive and already do not allow for ...

On CNBC's “Mad Money Lightning Round,” on Thursday, Jim Cramer said Recursion Pharmaceuticals (NASDAQ: RXRX) has been “horrendous” and he does not like to recommend horrendous stocks. On the earnings ...

AI-leveraged drug development has become an $18 billion industry, but companies in the sector are experiencing some hardships. Beyond efforts to convenience investors their drugs are safe and ...

Recursion now believes it has sufficient cash runway to reach the end of 2027, with partnerships potentially meaningfully extending this. For example, partnerships have provided Recursion with ...

In this week’s edition of InnovationRx, we look at a new biotech fund spearheaded by Recursion, a shift in bird flu strategy from the Trump Administration, a new vaccine approval from the FDA, ...

1 School of Education Science, Xinjiang Normal University, Urumqi, China. 2 School of Educational Technology, Beijing Normal University, Beijing, China. With the updating of knowledge and the ...